Highlights Curasight A/S

Equities

CURAS

DK0061295797

End-of-day quote NORDIC GROWTH MARKET Other stock markets 23:00:00 07/05/2024 BST			5-day change	1st Jan Change
10.5 ^DKK	+5.00%		+5.63%	-40.85%

04-16	Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	CI
04-12	Curasight A/S Announces Board Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Curasight A/S Announces Approval of Clinical Trial Application for Phase 2 Trial with uTRACE in Prostate Cancer Patients	04-16	CI
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Curasight A/S Announces Acceleration of Therapeutic Strategy to Strengthen Position as A Radiopharmaceutical Theranostic Company	02-13	CI
Curasight Gears Up for Phase II Study in Prostate Cancer	12-22	CI
Curasight A/S Submits Clinical Trial Application for Phase 2 Trial with Utrace	12-18	CI
Curasight A/S Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-23	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT[®] in lung cancer	18/10/23	CI
Curasight A/S Announces Positive Results from the Phase II Study of uTRACE in Brain Cancer Presented at the World Molecular Imaging Congress 2023 in Prague	14/09/23	CI
Curasight A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	24/08/23	CI
Curasight A/S Announces Positive Results in Upar-Pet/MR Phase II Study in Brain Cancer	29/06/23	CI
Curasight A/S Reports Positive Preclinical Results with uTREAT in Aggressive Brain Cancer (Glioblastoma)	07/06/23	CI
Curasight A/S Reports Earnings Results for the First Quarter Ended March 31, 2023	25/05/23	CI
Curasight Secures Global License Agreement for Utrace in Prostate Cancer	11/05/23	CI
Curasight A/S Enters into an Exclusive Global License and Collaboration Agreement with Curium Inc	01/05/23	CI
Annual Report for the fiscal year 2022	23/02/23	AQ
Year-end report October - December 2022	23/02/23	AQ
Curasight A/S Reports Earnings Results for the Full Year Ended December 31, 2022	23/02/23	CI
Curasight A/S Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23/02/23	CI
BioStock: Curasight eagerly awaiting phase II-results in brain cancer	01/12/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Curasight A/S

Equities

CURAS

DK0061295797

Highlights

Filters